Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice

Ehud Cohen; Johan F. Paulsson; Pablo Blinder; Tal Burstyn-Cohen; Deguo Du; Gabriela Estepa; Anthony Adame; Hang M. Pham; Martin Holzenberger; Jeffery W. Kelly; Eliezer Masliah; Andrew Dillin

doi:10.1016/j.cell.2009.11.014

Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice

Ehud Cohen, Johan F. Paulsson, Pablo Blinder, Tal Burstyn-Cohen, Deguo Du, Gabriela Estepa, Anthony Adame, Hang M. Pham, Martin Holzenberger, Jeffery W. Kelly, Eliezer Masliah, Andrew Dillin^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

410 Scopus citations

Abstract

The insulin/insulin growth factor (IGF) signaling (IIS) pathway is a key regulator of aging of worms, flies, mice, and likely humans. Delayed aging by IIS reduction protects the nematode C. elegans from toxicity associated with the aggregation of the Alzheimer's disease-linked human peptide, Aβ. We reduced IGF signaling in Alzheimer's model mice and discovered that these animals are protected from Alzheimer's-like disease symptoms, including reduced behavioral impairment, neuroinflammation, and neuronal loss. This protection is correlated with the hyperaggregation of Aβ leading to tightly packed, ordered plaques, suggesting that one aspect of the protection conferred by reduced IGF signaling is the sequestration of soluble Aβ oligomers into dense aggregates of lower toxicity. These findings indicate that the IGF signaling-regulated mechanism that protects from Aβ toxicity is conserved from worms to mammals and point to the modulation of this signaling pathway as a promising strategy for the development of Alzheimer's disease therapy.

Original language	English
Pages (from-to)	1157-1169
Number of pages	13
Journal	Cell
Volume	139
Issue number	6
DOIs	https://doi.org/10.1016/j.cell.2009.11.014
State	Published - 11 Dec 2009
Externally published	Yes

Bibliographical note

Funding Information:
We thank Dr. Hyun-Eui Kim for expert assistance with size-exclusion chromatography and Dr. Gustavo Dziewczapolski for assistance with behavioral assay. We thank the McKnight Foundation (A.D.) and NIA P01 AG031097 (A.D., J.W.K., E.M.) for funding. E.C. and A.D. designed and initiated this study. E.C. crossed the mouse strains and performed the behavioral assays, quantitative PCR, ELISA, size exclusion, and WB experiments. T.B.C. performed IHC assays. Immunoelectron microscopy was carried out by J.F.P. D.D. executed in vitro kinetic aggregation assays. P.B. performed image processing of the EM data. A.A. assisted with IHC. G.E. assisted with mice genotyping and behavioral assays. H.M.P. assisted with WB. M.H. provided Igf1r +/− mice and expertise pertinent to Igf1r. E.C., A.D., J.W.K., and E.M. wrote the manuscript. A.D. and J.W.K. are founders of Proteostasis Therepeutics Inc. and disclose no conflict of interest in this study.

Keywords

HUMDISEASE
PROTEINS
SIGNALING

Access to Document

10.1016/j.cell.2009.11.014

Cite this

@article{7b8b946636fb424f84abc2735bae8c71,

title = "Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice",

abstract = "The insulin/insulin growth factor (IGF) signaling (IIS) pathway is a key regulator of aging of worms, flies, mice, and likely humans. Delayed aging by IIS reduction protects the nematode C. elegans from toxicity associated with the aggregation of the Alzheimer's disease-linked human peptide, Aβ. We reduced IGF signaling in Alzheimer's model mice and discovered that these animals are protected from Alzheimer's-like disease symptoms, including reduced behavioral impairment, neuroinflammation, and neuronal loss. This protection is correlated with the hyperaggregation of Aβ leading to tightly packed, ordered plaques, suggesting that one aspect of the protection conferred by reduced IGF signaling is the sequestration of soluble Aβ oligomers into dense aggregates of lower toxicity. These findings indicate that the IGF signaling-regulated mechanism that protects from Aβ toxicity is conserved from worms to mammals and point to the modulation of this signaling pathway as a promising strategy for the development of Alzheimer's disease therapy.",

keywords = "HUMDISEASE, PROTEINS, SIGNALING",

author = "Ehud Cohen and Paulsson, {Johan F.} and Pablo Blinder and Tal Burstyn-Cohen and Deguo Du and Gabriela Estepa and Anthony Adame and Pham, {Hang M.} and Martin Holzenberger and Kelly, {Jeffery W.} and Eliezer Masliah and Andrew Dillin",

note = "Funding Information: We thank Dr. Hyun-Eui Kim for expert assistance with size-exclusion chromatography and Dr. Gustavo Dziewczapolski for assistance with behavioral assay. We thank the McKnight Foundation (A.D.) and NIA P01 AG031097 (A.D., J.W.K., E.M.) for funding. E.C. and A.D. designed and initiated this study. E.C. crossed the mouse strains and performed the behavioral assays, quantitative PCR, ELISA, size exclusion, and WB experiments. T.B.C. performed IHC assays. Immunoelectron microscopy was carried out by J.F.P. D.D. executed in vitro kinetic aggregation assays. P.B. performed image processing of the EM data. A.A. assisted with IHC. G.E. assisted with mice genotyping and behavioral assays. H.M.P. assisted with WB. M.H. provided Igf1r +/− mice and expertise pertinent to Igf1r. E.C., A.D., J.W.K., and E.M. wrote the manuscript. A.D. and J.W.K. are founders of Proteostasis Therepeutics Inc. and disclose no conflict of interest in this study. ",

year = "2009",

month = dec,

day = "11",

doi = "10.1016/j.cell.2009.11.014",

language = "אנגלית",

volume = "139",

pages = "1157--1169",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier B.V.",

number = "6",

}

TY - JOUR

T1 - Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice

AU - Cohen, Ehud

AU - Paulsson, Johan F.

AU - Blinder, Pablo

AU - Burstyn-Cohen, Tal

AU - Du, Deguo

AU - Estepa, Gabriela

AU - Adame, Anthony

AU - Pham, Hang M.

AU - Holzenberger, Martin

AU - Kelly, Jeffery W.

AU - Masliah, Eliezer

AU - Dillin, Andrew

N1 - Funding Information: We thank Dr. Hyun-Eui Kim for expert assistance with size-exclusion chromatography and Dr. Gustavo Dziewczapolski for assistance with behavioral assay. We thank the McKnight Foundation (A.D.) and NIA P01 AG031097 (A.D., J.W.K., E.M.) for funding. E.C. and A.D. designed and initiated this study. E.C. crossed the mouse strains and performed the behavioral assays, quantitative PCR, ELISA, size exclusion, and WB experiments. T.B.C. performed IHC assays. Immunoelectron microscopy was carried out by J.F.P. D.D. executed in vitro kinetic aggregation assays. P.B. performed image processing of the EM data. A.A. assisted with IHC. G.E. assisted with mice genotyping and behavioral assays. H.M.P. assisted with WB. M.H. provided Igf1r +/− mice and expertise pertinent to Igf1r. E.C., A.D., J.W.K., and E.M. wrote the manuscript. A.D. and J.W.K. are founders of Proteostasis Therepeutics Inc. and disclose no conflict of interest in this study.

PY - 2009/12/11

Y1 - 2009/12/11

N2 - The insulin/insulin growth factor (IGF) signaling (IIS) pathway is a key regulator of aging of worms, flies, mice, and likely humans. Delayed aging by IIS reduction protects the nematode C. elegans from toxicity associated with the aggregation of the Alzheimer's disease-linked human peptide, Aβ. We reduced IGF signaling in Alzheimer's model mice and discovered that these animals are protected from Alzheimer's-like disease symptoms, including reduced behavioral impairment, neuroinflammation, and neuronal loss. This protection is correlated with the hyperaggregation of Aβ leading to tightly packed, ordered plaques, suggesting that one aspect of the protection conferred by reduced IGF signaling is the sequestration of soluble Aβ oligomers into dense aggregates of lower toxicity. These findings indicate that the IGF signaling-regulated mechanism that protects from Aβ toxicity is conserved from worms to mammals and point to the modulation of this signaling pathway as a promising strategy for the development of Alzheimer's disease therapy.

AB - The insulin/insulin growth factor (IGF) signaling (IIS) pathway is a key regulator of aging of worms, flies, mice, and likely humans. Delayed aging by IIS reduction protects the nematode C. elegans from toxicity associated with the aggregation of the Alzheimer's disease-linked human peptide, Aβ. We reduced IGF signaling in Alzheimer's model mice and discovered that these animals are protected from Alzheimer's-like disease symptoms, including reduced behavioral impairment, neuroinflammation, and neuronal loss. This protection is correlated with the hyperaggregation of Aβ leading to tightly packed, ordered plaques, suggesting that one aspect of the protection conferred by reduced IGF signaling is the sequestration of soluble Aβ oligomers into dense aggregates of lower toxicity. These findings indicate that the IGF signaling-regulated mechanism that protects from Aβ toxicity is conserved from worms to mammals and point to the modulation of this signaling pathway as a promising strategy for the development of Alzheimer's disease therapy.

KW - HUMDISEASE

KW - PROTEINS

KW - SIGNALING

UR - http://www.scopus.com/inward/record.url?scp=71449108913&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2009.11.014

DO - 10.1016/j.cell.2009.11.014

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 20005808

AN - SCOPUS:71449108913

SN - 0092-8674

VL - 139

SP - 1157

EP - 1169

JO - Cell

JF - Cell

IS - 6

ER -

Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this